Deal scores initial production volumes ahead of facility's planned launch next year
Lotte Biologics said Tuesday it has secured its first major commercial manufacturing contract for its Songdo Bio Campus in Incheon, highlighting a milestone in the company's expansion into the global biopharmaceutical contract manufacturing market.
According to Lotte Biologics, the agreement marked an initial order ahead of the facility's full-scale operations scheduled for next year. The names of the client and its products, as well as the financial terms of the agreement, were not disclosed.
Under the agreement, Lotte Biologics will provide manufacturing services covering the production of drug substances for clinical-stage products through to finished pharmaceuticals, offering an integrated manufacturing solution for the client's key products.
Unlike the conventional approach of ramping up customer acquisition after a facility becomes operational, Lotte Biologics has pursued contracts during the design and construction stages. The strategy is intended to secure production volumes early and establish a revenue base from the beginning of commercial operations.
The company expects the contract to help stabilize the initial utilization of its Songdo facility and strengthen its position in the global contract development and manufacturing organization market.
Songdo Plant 1, which has a total production capacity of 120,000 liters, is equipped with eight stainless steel bioreactors, each with a capacity of 15,000 liters.
The contract also advances Lotte Biologics' dual-site strategy, which connects its existing Syracuse Bio Campus in New York with its new manufacturing hub in South Korea. Lotte completed the acquisition of Bristol Myers Squibb's Syracuse biopharmaceutical manufacturing plant in New for $160 million in January 2023.
The company aims to combine Syracuse's established commercial manufacturing experience with Songdo's production capacity to diversify its global supply chain and provide customers with greater manufacturing flexibility.
Lotte Biologics' Syracuse facility has accumulated more than 62 regulatory approvals, providing a foundation for quality management and regulatory compliance.
Lotte Biologics plans to apply the quality management systems and regulatory expertise developed in Syracuse to its Songdo operations, establishing consistent manufacturing standards across the two sites.
"This agreement is a strong endorsement of our strategy and the confidence our customers place in Lotte Biologics," James Park, co-CEO of Lotte Biologics, said.
"By combining Syracuse’s proven expertise with Songdo’s advanced infrastructure, we are well positioned to support our partners’ success and bring life-changing medicines to patients worldwide.”
hwkan@heraldcorp.com
